# Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients

> **NCT02062489** · PHASE3 · RECRUITING · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 688 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Tamoxifen
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02062489
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2014-05
- **Primary completion:** 2025-05
- **Final completion:** 2026-05
- **Target enrollment:** 688 (ESTIMATED)
- **Last updated:** 2022-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02062489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02062489, "Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients". Retrieved via MORVS 2026-10-13 from https://api.morvs.ai/clinical/NCT02062489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*